AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6437366
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate and imipramine combination
Trial: 26546298
Drug: Hysteroscopic local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic local anesthetic intrauterine cornual block (ICOB) plus direct local anesthetic cervical block (DCB) using 1 mL 3% mepivacaine plus 1 mL 0.5% bupivacaine
Trial: 26546298
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving DCB plus ICOB with 2 mL of placebo (saline)
Trial: 23465084
Drug: Moderate doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate doses of lithium plus optimized treatment (OPT)
Trial: 25827507
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment (OPT) alone
Trial: 20626016
Drug: Child-targeted intervention
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-targeted intervention involving massage and humor therapy
Trial: 17597711
Drug: GI181771X (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI181771X (selective CCK‐A agonist)
Trial: 12218519
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine pretraumatic injection
Trial: 12218519
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine posttraumatic injection
Trial: 12218519
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) pretraumatic injection
Trial: 12218519
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) posttraumatic injection
Trial: 11783195
Drug: Salvia injection
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia injection (SI)
Trial: 11783195
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and western medicine (TCM‐WM)
Trial: 8684533
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment for an average period of 18 months
Trial: 16316784
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid treatment
Trial: 6295861
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Ranitidine at night
Trial: 6295861
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid when necessary
Trial: 27398918
Drug: GAA 15
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAA 15 training program (15 minutes of neuromuscular training exercises, twice weekly for 8 weeks)
Trial: 11509470
Drug: 256-mg ferrous
RxNorm normalized name: ferrous gluconate 256 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 256-mg ferrous sulfate daily for 4 weeks
Trial: 7958150
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of fluconazole
Trial: 7958150
Drug: Single intravaginal
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravaginal dose of 500 mg clotrimazole
Trial: 10991886
Drug: Praziquantel (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (1,800 mg) with high-lipid diet
Trial: 10991886
Drug: Praziquantel (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (1,800 mg) with high-carbohydrate diet
Trial: 3898905
Drug: Intranasal flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal flunisolide 50 micrograms per nostril b.i.d.
Trial: 3898905
Drug: Oral flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flunisolide 500 micrograms b.i.d.
Trial: 3898905
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal and oral) b.i.d.
Trial: 31276193
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (IV fluid therapy)
Trial: 25125506
Drug: Methazolamide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (40 mg b.i.d.)
Trial: 23299270
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheets applied to half of the scar for 6 months
Trial: 23299270
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheets
Trial: 20708858
Drug: Threat condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threat condition (believing they ingested 500 mg of disulfiram)
Trial: 16208302
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion sessions (10 sessions, twice a week for 5 weeks)
Trial: 16208302
Drug: AcupunctureSham (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AcupunctureSham (10 sessions, twice a week for 5 weeks)
Trial: 12654073
Drug: Sensory integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory integrative therapy (n=15)
Trial: 12654073
Drug: Vestibular stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular stimulation in addition to sensory integrative therapy (n=15)
Trial: 12654073
Drug: Neurodevelopmental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental therapy (n=15)
Trial: 10477025
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment room lasers
Trial: 8394538
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of Aza-CsA-P, n = 41
Trial: 8394538
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy of Aza-P, n = 42
Trial: 27196093
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine multilevel intervention (MLI)
Trial: 27196093
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine multilevel intervention (comparison group)
Trial: 27802242
Drug: Safinamide 100
RxNorm normalized name: safinamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide 100 mg/day
Trial: 22948897
Drug: Safinamide 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide 350 mg/day
Trial: 22948897
Drug: Phenelzine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine 30 mg/day
Trial: 20004013
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL water (placebo) (n=285)
Trial: 18203329
Drug: Control (DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (DMARD therapy)
Trial: 9469328
Drug: Letrozole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 0.5 mg
Trial: 1515448
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium blocker
Trial: 7654578
Drug: Amorolfine cream
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine cream 0.5%
Trial: 2689018
Drug: Bifonazole cream
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole cream 1%
Trial: 788464
Drug: Long-acting amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting amitriptyline (Diffucaps) 25 mg at evening meal
Trial: 788464
Drug: Ordinary amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary amitriptyline 40 mg at bedtime
Trial: 28556506
Drug: Fosdagrocorat 5
RxNorm normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosdagrocorat 5 mg
Trial: 23870174
Drug: Argan oil
RxNorm normalized name: ARGAN OIL
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argan oil (25 mL/day for 3 weeks)
Trial: 21585288
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg p.o. (positive control)
Trial: 21585288
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 μg/day p.o. for 14 days
Trial: 21585288
Drug: Roflumilast 1000
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 1000 μg/day p.o. for 14 days
Trial: 7953259
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg per rectum
Trial: 7953259
Drug: Pethidine 50
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 50 mg intravenously
Trial: 7953259
Drug: Pethidine with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine with intravenous benzodiazepines
Trial: 2441163
Drug: Caffeine alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine alone, 250 mg intravenously (i.v.)
Trial: 2441163
Drug: Adenosine alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine alone, increasing dose of 0.04‐0.16 mg/kg/min
Trial: 2441163
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion after caffeine
Trial: 30151409
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single dose every 6 months)
Trial: 30151409
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single dose every 6 months)
Trial: 26242149
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine treatment (anastrozole, exemestane)
Trial: 26242149
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (doxorubicin plus paclitaxel)
Trial: 26242149
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with trastuzumab
Trial: 23108194
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily for 60 days
Trial: 10809397
Drug: Remineralizing solution
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remineralizing solution only (Group A)
Trial: 10809397
Drug: 35% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% phosphoric acid etching for 30 s + remineralizing solution (Group B)
Trial: 10809397
Drug: Remineralizing solution
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remineralizing solution + daily fluoride toothpaste slurry (1,000 ppm for 5 min) (Group C)
Trial: 10809397
Drug: 35% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% phosphoric acid etching + daily fluoride treatment (Group D)
Trial: 1354432
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 0.1 g
Trial: 1354432
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 0.2 g
Trial: 1354432
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 0.2 g with Maalox 70 (10 ml 2h and 10 ml 15 min before)
Trial: 1354432
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 0.2 g with famotidine (40 mg 1h before)
Trial: 6896649
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.2 mg kg‐1 in 10% dextrose solution)
Trial: 6896649
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine (0.2 mg kg‐1 in 0.9% saline)
Trial: 6896649
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine (0.2 mg kg‐1 in 0.9% saline)
Trial: 31194778
Drug: Oral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatments (risperidone, olanzapine)
Trial: 31194778
Drug: Oral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatments (clozapine, olanzapine)
Trial: 31194778
Drug: Long-acting treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting treatment switched from another long-acting
Trial: 29701875
Drug: Treatment (dengue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (dengue vaccine)
Trial: 17057048
Drug: Full-dose TIV
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose TIV (n = 222)
Trial: 17057048
Drug: Half-dose TIV
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose TIV (n = 222)
Trial: 9240642
Drug: Postoperative inguinofemoral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative inguinofemoral radiation therapy (Group 1, 65 patients)
Trial: 9240642
Drug: No inguinofemoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inguinofemoral radiation therapy (Group 2, 70 patients)
Trial: 8252455
Drug: Aminophylline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (2 mg/kg, i.v.)
Trial: 25712760
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri Prodentis (one tablet every 24 hours for 30 days)
Trial: 25712760
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered after probiotic treatment for 6 months)
Trial: 21771281
Drug: Vardenafil (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (starting dose 10 mg, titratable to 5 mg or 20 mg after 4 weeks)
Trial: 16923005
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) in patients with prior RVAP (Group A)
Trial: 16923005
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) in patients without prior RVAP (Group B)
Trial: 14698860
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of methylprednisolone
Trial: 3524436
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BW942C and TMP-SMX
Trial: 29370942
Drug: Analgesic consumption
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic consumption
Trial: 24108237
Drug: Control (Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Amlodipine monotherapy)
Trial: 20332721
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTA) injection in triceps surae muscles
Trial: 18164245
Drug: Nolomirole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nolomirole (5 mg b.i.d.)
Trial: 17051490
Drug: Azithromycin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (750 mg twice daily) + Artesunate (100 mg twice daily)
Trial: 17051490
Drug: Azithromycin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1000 mg once daily) + Artesunate (200 mg once daily)
Trial: 17051490
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg 3 times daily) + Quinine (10 mg/kg 3 times daily)
Trial: 17051490
Drug: Azithromycin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (750 mg twice daily) + Quinine (10 mg/kg twice daily)
Trial: 12743434
Drug: Omeprazole MUPS
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole MUPS 40 mg
Trial: 11187917
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose cytarabine with high-dose methotrexate during interval therapy (trial 58881)
Trial: 11187917
Drug: Leukocyte counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leukocyte counts >100 x 10(9)/l, specific genetic abnormalities, poor initial response to steroids, high level of minimal residual disease (trial 58881)
Trial: 8466005
Drug: 0.9 micrograms.kg‐1.min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 micrograms.kg‐1.min‐1 of intravenous nitroglycerin
Trial: 28071044
Drug: 3.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/d CLA for 12 weeks
Trial: 23670305
Drug: SBR759 (3‐,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759 (3‐, 6‐, 9‐, 12‐g/day)
Trial: 23670305
Drug: Placebo (12‐g/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12‐g/day)
Trial: 18759356
Drug: CP-101,606 (NR2B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-101,606 (NR2B selective NMDA glutamate antagonist)
Trial: 15821528
Drug: Duloxetine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (80 mg daily) + Pelvic Floor Muscle Training (PFMT)
Trial: 15821528
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Duloxetine + PFMT)
Trial: 1681224
Drug: Long-acting chloramphenicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting chloramphenicol (double injection on admission and 48 hours later)
Trial: 1681224
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin (8 days, 4 times a day)
Trial: 6619812
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of inactivated hepatitis B vaccine (20 micrograms) by automatic jet injection
Trial: 22480620
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo injections
Trial: 21968360
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg loading dose followed by 50 mg every 12 h)
Trial: 19793213
Drug: CORT (Corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT (Corticosteroid injections)
Trial: 17999899
Drug: Thrombolytic drugs
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic drugs administered intraventricularly through an external ventricular drain
Trial: 9809092
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml of 0.5% hyperbaric bupivacaine solution
Trial: 9809092
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 0.5% hyperbaric bupivacaine solution
Trial: 9809092
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 0.5% hyperbaric bupivacaine solution
Trial: 7534838
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group B)
Trial: 31505302
Drug: Local retropharyngeal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local retropharyngeal steroids
Trial: 31505302
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no retropharyngeal steroids)
Trial: 22320714
Drug: 5000 ppm
RxNorm normalized name: Sodium Fluoride 5000 PPM
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5000 ppm F; twice a day
Trial: 22320714
Drug: 5000 ppm;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 ppm; twice a day, plus the 'massage' method once a day
Trial: 22320714
Drug: 1450 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1450 ppm F; twice a day